Midkine can not be accepted as a new biomarker for unexplained female infertility-Reference-Cited by-同舟云学术

Midkine can not be accepted as a new biomarker for unexplained female infertility

Published:2023-10-06 Issue:6 Volume:48 Page:698-708
ISSN:1303-829X
Container-title:Turkish Journal of Biochemistry
language:en
Short-container-title:

Author:

Ergüven Mine¹^ORCID,Kahraman Semra²^ORCID,Pirkevi Caroline²^ORCID,İrez Tülay³^ORCID

Affiliation:

1. Department of Medical Biochemistry, Faculty of Medicine , İstanbul Aydın University , İstanbul , Türkiye

2. In Vitro Fertilisation , Memorial Hospital , İstanbul , Türkiye

3. Department of Histology and Embryology, Faculty of Medicine , T. C. İstanbul Yeni Yüzyıl University , İstanbul , Türkiye

Abstract

Abstract Objectives This study aimed to investigate whether a growth factor and a cytokine midkine (MK) can be a new biomarker for the diagnosis and treatment of unexplained female infertility (UFI) cases. Methods Serum (S), follicle fluid (FF), and cumulus cells (CCs) of the patients aged 20–42 years, diagnosed with male factor (MF) and UFI were used. Patients underwent Intracytoplasmic Sperm Injection (ICSI). The anti-Müllerian hormone (AMH) and MK levels with other hormone levels (FSH, LH, E2, PRL, INHB, TSH), the oocyte and embryo qualities, the fertilization and pregnancy rates, and cumulus cells (Cell number and ultrastructure, apoptosis rate) were evaluated. Student-T-test was performed and p<0.05 was considered statistically significant. Results The lowest numbers of CCs were found at UFI (p<0.05). The lowest apoptosis rate with the highest CC viability rate was evaluated at MF (p<0.05). The lowest AMH and MK levels (S, FF) were detected at UFI in comparison to MF (p<0.05). MK and AMH levels of non-pregnant subjects were much lower than pregnant subjects (p<0.05). In addition, these levels were lower in the subjects above 35 age (p<0.05). Structural analysis of CCs showed that the number of lytic cells with cell remnants and apoptotic bodies was higher in non-pregnant subjects. It seems that MK did not show any resistance to both AMH and apoptosis. Conclusions MK can not be accepted as a new biomarker for the diagnosis and treatment monitoring of UFI cases.

Publisher

Walter de Gruyter GmbH

Subject

Biochemistry (medical),Clinical Biochemistry,Molecular Biology,Biochemistry

Link

https://www.degruyter.com/document/doi/10.1515/tjb-2023-0055/pdf

Reference52 articles.

1. Dewailly, D, Andersen, CY, Balen, A, Broekmans, F, Dilaver, N, Fanchin, R, et al.. The physiology and clinical utility of anti-Mullerian hormone in women. Hum Reprod Update 2014;20:370–85. https://doi.org/10.1093/humupd/dmt062.

2. Garg, D, Tal, R. The role of AMH in the pathophysiology of polycystic ovarian syndrome. Reprod Biomed Online 2016;33:15–28. https://doi.org/10.1016/j.rbmo.2016.04.007.

3. Cohen, J, Chabbert-Buffet, N, Darai, E. Diminished ovarian reserve, premature ovarian failure, poor ovarian responder--a plea for universal definitions. J Assist Reprod Genet 2015;32:1709–12. https://doi.org/10.1007/s10815-015-0595-y.

4. Broer, SL, Broekmans, FJ, Laven, JS, Fauser, BC. Anti-Müllerian hormone: ovarian reserve testing and its potential clinical implications. Hum Reprod Update 2014;20:688–701. https://doi.org/10.1093/humupd/dmu020.

5. Overbeek, A, Broekmans, FJ, Hehenkamp, WJ, Wijdeveld, ME, van Disseldorp, J, van Dulmen-den Broeder, E, et al.. Intra-cycle fluctuations of anti-Müllerian hormone in normal women with a regular cycle: a re-analysis. Reprod Biomed Online 2012;24:664–9. https://doi.org/10.1016/j.rbmo.2012.02.023.